Business Context and Reporting Period
This Form 8-K filing by Organovo Holdings, Inc. (ONVO) reports a corporate action effective March 20, 2025. The company, incorporated in Delaware and headquartered in San Diego, California, is a biotechnology firm focused on 3D bioprinting. The filing addresses a material modification to the rights of security holders regarding the company's capital structure.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the mechanics of a reverse stock split. The only financial figure disclosed is the closing sales price of the Common Stock on March 19, 2025, which serves as the basis for cash payments in lieu of fractional shares, though the specific dollar amount is not explicitly stated in the text provided.
Material Changes
- Reverse Stock Split: The company executed a 1-for-12 reverse stock split of its common stock.
- Share Consolidation: Every 12 pre-split shares were combined into 1 post-split share.
- Fractional Shares: No fractional shares were issued; holders received cash in lieu of fractions based on the March 19, 2025 closing price.
- Ownership: The split did not alter any record holder's percentage ownership interest, except for de minimis changes due to fractional share elimination.
- Equity Plans: The number of shares available for issuance under equity incentive plans was proportionately adjusted.
Outlook, Risks, and Management Commentary
Purpose: The primary objective of the reverse stock split is to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share to ensure continued listing.
Implementation: The split was approved by stockholders at the November 20, 2024 Annual Meeting, with the Board setting the ratio at 1-for-12 on March 6, 2025. The action became effective at 5:00 p.m. Eastern Time on March 20, 2025.
Trading Details: Trading on a split-adjusted basis commenced on March 21, 2025. The trading symbol remains "ONVO," but the CUSIP number changed to 68620A302.
Risks/Contingencies: The filing notes that the summary of the Certificate of Amendment is qualified by reference to the full text attached as Exhibit 3.1.
Investor Verification Checklist
- Verify the new CUSIP number (68620A302) for accurate trading and record-keeping.
- Confirm the cash payment amount received for fractional shares, if applicable, based on the March 19, 2025 closing price.
- Monitor the stock price post-split to ensure it meets the $1.00 minimum bid price requirement for continued Nasdaq listing.
- Review the adjusted share counts in brokerage accounts to ensure the 1-for-12 consolidation was applied correctly.
- Check for any subsequent filings regarding the company's compliance status with Nasdaq listing standards.